Cahill represented the lead arrangers in the transaction. Horizon Therapeutics USA, Inc. executed its $1.6 billion incremental term B credit facility. Proceeds from the credit facility were...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here